Entera Bio and OPKO Biologics have joined forces in a research collaboration to advance the development of oral peptide tablet formulations designed to address obesity and intestinal malabsorption syndromes.
Under the terms of agreement, OPKO will provide its exclusive long-acting GLP-2 peptide along with specific analogs of Oxyntomodulin (OXM) to be used in the creation of oral tablet formulations, leveraging Entera's specialised oral delivery technology.
This collaboration with OPKO signifies a significant step in expanding the application of oral delivery technology to encompass a wider range of valuable peptides.
It is challenging to administer peptides orally due to their rapid degradation within the gastrointestinal tract and limited permeability. GLP-2 analogs have demonstrated the ability to enhance nutrient absorption in patients afflicted with short bowel syndrome (SBS) and subsequently reduce their reliance on parenteral support.
The current FDA-approved GLP-2 analog, Teduglutide, necessitates daily subcutaneous injections. In SBS patients, oral drug delivery is especially problematic, as the absorptive capacity of the intestine is diminished due to its shortened length and reduced functionality.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!